Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 9, 2008, Pages 1729-1733

  Lucignani, Giovanni ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211; BISMUTH 212; MUCIN 1; TENASCIN; TRASTUZUMAB;

ALPHA RADIATION; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CELL STRAIN MCF 7; CYCLOTRON; DRUG DOSE INCREASE; GLIOBLASTOMA; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INOCULATION; ISOTOPE LABELING; MAXIMUM TOLERATED DOSE; NONHUMAN; NUDE MOUSE; OLIGODENDROGLIOMA; OVARY CARCINOMA; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; RADIOISOTOPE DECAY; SCINTILLATION CAMERA; SHORT SURVEY; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT RESPONSE;

ALPHA PARTICLES; ANIMALS; ANTINEOPLASTIC AGENTS; ASTATINE; BISMUTH; BRAIN NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 50449091972     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0856-4     Document Type: Short Survey

References (15)

1. M Chérel F Davodeau F Kraeber-Bodéré JF Chatal 2006 Current status and perspectives in alpha radioimmunotherapy Q J Nucl Med Mol Imaging 50 4 322 329
2. MR Zalutsky DA Reardon OR Pozzi G Vaidyanathan DD Bigner 2007 Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies Nucl Med Biol 34 7 779 785
3. MW Brechbiel 2007 Targeted alpha-therapy: past, present, future? Dalton Trans 21 43 4918 4928
4. HS Chong X Ma T Le B Kwamena DE Milenic ED Brady 2008 Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy J Med Chem 51 1 118 125
5. MR Zalutsky DA Reardon G Akabani RE Coleman AH Friedman HS Friedman 2008 Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6 J Nucl Med 49 1 30 38
6. JG Jurcic SM Larson G Sgouros MR McDevitt RD Finn CR Divgi 2002 Targeted alpha particle immunotherapy for myeloid leukemia Blood 100 4 1233 1239
7. S Nilsson RH Larsen SD Fosså L Balteskard KW Borch JE Westlin 2005 First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases Clin Cancer Res 11 12 4451 4459
8. C Nieder M Adam M Molls AL Grosu 2006 Therapeutic options for recurrent high-grade glioma in adult patients: recent advances Crit Rev Oncol Hematol 60 3 181 193
9. S Palm T Bäck I Claesson A Danielsson J Elgqvist S Frost 2007 Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice Int J Radiat Oncol Biol Phys 69 2 572 579
10. EY Song CF Qu SM Rizvi C Raja J Beretov A Morgenstern 2008 Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model Cancer Biol Ther 7 1 76 80
11. 213Bi-C- functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy Clin Cancer Res 13 18 Pt 2 5604s 5612s
12. MK Robinson C Shaller K Garmestani PS Plascjak KM Hodge QA Yuan 2008 Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies Clin Cancer Res 14 3 875 882
13. Y Almqvist AC Steffen H Lundqvist H Jensen V Tolmachev A Sundin 2007 Biodistribution of 211At-labeled humanized monoclonal antibody A33 Cancer Biother Radiopharm 22 4 480 487
14. A Walte SS Sriyapureddy Z Korkmaz D Krull O Bolte M Hofmann 2007 Preparation and evaluation of 211At labelled antineoplastic antibodies J Pharm Pharm Sci 10 2 277s 285s
15. CA Boswell MW Brechbiel 2007 Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view Nucl Med Biol 34 7 757 778